Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL829889 | 0.73 | MAPT (0.34) | ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL829408 | 0.72 | SMN1; SMN2 (0.37) | ALDH1A1MAPT | |
| SCHEMBL10281706 | 0.69 | CYP3A4 (0.60) | ALDH1A1MAPTKDM4ECYP3A4GABRB3 | |
| Hydrochloric Acid SCHEMBL829746 | 0.69 | SMN1; SMN2 (0.41) | ALDH1A1MAPTKDM4E | |
| SCHEMBL17791220 | 0.67 | LMNA (0.66) | MAPT | |
| SCHEMBL11677957 | 0.67 | LMNA (0.47) | ALDH1A1KDM4ECYP3A4GABRB3OPRD1 | |
| SCHEMBL828772 | 0.66 | ELANE (0.53) | ALDH1A1MAPTKDM4E | |
| SCHEMBL16200785 | 0.65 | FPR2 (0.37) | ALDH1A1KDM4ECYP3A4GABRB3OPRD1 | |
| SCHEMBL19670119 | 0.64 | CNR1 (0.31) | — | |
| SCHEMBL6890760 | 0.62 | MMP9 (0.36) | ALDH1A1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004614-B1 | TETRAHALOGENATED COMPOUNDS USEFUL AS INHIBITORS OF ANGIOGENESIS | US GOV HEALTH & HUMAN SERV (US) | 2016-10-19 | — | — | EP | disclosed |
| US-8143252-B2 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090186913-A1 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE GOVERNMENT OF THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186913-A1 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | VHL, TEK, FLT4 | ALDH1A1 679/4885MAPT 2918/4885KDM4E 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.